预测维多珠单抗治疗溃疡性结肠炎的无皮质类固醇内镜缓解
研究利用维多珠单抗3期临床试验数据,构建随机森林模型预测溃疡性结肠炎患者第52周无皮质类固醇内镜缓解。基线数据预测AuROC仅0.62,而使用至第6周数据预测AuROC为0.73。模型预测的缓解者中59%达到无皮质类固醇内镜缓解,非缓解者中仅21%。
要点
- 使用至第6周数据的机器学习模型可预测第52周无皮质类固醇内镜缓解,AuROC为0.73。
- 基线数据预测能力有限,AuROC仅0.62。
- 第6周粪便钙卫蛋白≤234 μg/g的预测几乎同样准确。
核心结论
- 使用维多珠单抗治疗至第6周的实验室数据的机器学习算法能准确识别哪些溃疡性结肠炎患者将在第52周达到无皮质类固醇内镜缓解。
研究设计与样本
- 从临床试验数据请求网站获取维多珠单抗3期临床试验数据,随机森林模型在70%数据上训练、30%数据上测试,使用491名受试者的基线数据或至第6周数据预测第52周无皮质类固醇内镜缓解。
主要发现
- 使用基线数据预测第52周无皮质类固醇内镜缓解的AuROC为0.62(95%CI:0.53-0.72)。
- 使用至第6周数据预测第52周无皮质类固醇内镜缓解的AuROC为0.73(95%CI:0.65-0.82)。
- 预测为缓解者的受试者占47%,其中59%达到无皮质类固醇内镜缓解;预测为非缓解者中21%达到无皮质类固醇内镜缓解。
- 使用第6周粪便钙卫蛋白≤234 μg/g的预测几乎同样准确。
关键数值与推荐
- 第6周粪便钙卫蛋白≤234 μg/g用于预测第52周无皮质类固醇内镜缓解。
临床怎么用
- 该算法可对临床决策产生重要影响,用于决定在维多珠单抗治疗最初6周临床获益不明显时是否继续使用该昂贵药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vedolizumab is an effective therapy for ulcerative colitis (UC), but costly and slow to work. New clinical responses occur after 30 weeks of therapy. AIMS: To enable physicians, patients, and insurers to predict whether a patient with UC will respond to vedolizumab at an early time point after starting therapy. METHODS: The clinical study data request website provided the phase 3 clinical trial data for vedolizumab. Random forest models were trained on 70% and tested on 30% of the data to predict corticosteroid-free endoscopic remission at week 52. Models were constructed using baseline data, or data through week 6 of vedolizumab therapy from 491 subjects. RESULTS: The AuROC for prediction of corticosteroid-free endoscopic remission at week 52 using baseline data was only 0.62 (95% CI: 0.53-0.72), but was 0.73 (95% CI: 0.65-0.82) when using data through week 6. A total of 47% of subjects were predicted to be remitters, and 59% of these subjects achieved corticosteroid-free endoscopic remission, in contrast to 21% of the predicted non-remitters. A week 6 prediction using FCP ≤234 μg/g was nearly as accurate. CONCLUSIONS: A machine learning algorithm using laboratory data through week 6 of vedolizumab therapy was able to accurately identify which UC patients would achieve corticosteroid-free endoscopic remission on vedolizumab at week 52. Application of this algorithm could have significant implications for clinical decisions on whom to continue on this costly medication when the benefits of the vedolizumab are not clinically apparent in the first 6 weeks of therapy.
引用
- Waljee AK, Liu B, Sauder K, et al. Predicting corticosteroid-free endoscopic remission with vedolizumab in ulcerative colitis. Aliment Pharmacol Ther. 2018. PMID: 29359519. doi:10.1111/apt.14510
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。